NCT06120140 2026-03-13
COCOON
Janssen Research & Development, LLC
Phase 2 Recruiting
Clinical Trials
16 trialsNCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT05498428 2026-02-13
PALOMA-2
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06268210 2026-02-09
NeoLazer
Yonsei University
Phase 2 Recruiting
NCT05786430 2026-01-27
LUCAS
Yonsei University
Phase 2 Active not recruiting
NCT05601973 2026-01-21
AMAZE-lung
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT06667076 2026-01-16
COPERNICUS
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT04965090 2025-12-18
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05299125 2025-10-01
AMIGO-1
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05541822 2025-05-22
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
Phase 2 Recruiting
NCT06156527 2023-12-05
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
National Cancer Center, Korea
Phase 2 Recruiting
NCT05338619 2023-09-01
PLATINUM
Korea University Guro Hospital
Phase 2 Unknown
NCT06020989 2023-09-01
CHAMELEON
Yonsei University
Phase 2 Unknown
NCT05701384 2023-01-27
Lazertinib 160mg in EGFR T790M NSCLC
Samsung Medical Center
Phase 2 Unknown
NCT05477615 2022-07-28
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
Seoul St. Mary's Hospital
Phase 2 Unknown
NCT05167851 2021-12-22
The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
Yonsei University
Phase 2 Unknown